RI2 THE EXCESS COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A MANAGED-CARE PERSPECTIVE  by Boulanger, L et al.
222 Abstracts
daily living limitations, supplemental insurance coverage and
region. We also examined whether prescription drug coverage
modiﬁed the difference in expenditures among enrollees with
asthma. RESULTS: Medicare beneﬁciaries with asthma had
higher mean Part A expenditures ($4412 versus $2744), longer
average hospital stays (3.53 days versus 1.82), and higher 
Part B expenditures ($3688 versus $2547) than those without
asthma. In regression analysis, asthma increased mean Part A
expenditures by $850 and Part B expenditures by $551. Outpa-
tient prescription drug coverage decreased Part B spending on
persons with asthma by $446, but increased Part B spending by
$243 for those without asthma. Prescription drug coverage had
no effect on either Part A expenditures or the number of days
spent in the hospital for either those with or those without
asthma. CONCLUSIONS: Asthma increases expenditures in the
Medicare program, but the increase is moderated by outpatient
prescription drug coverage. This suggests that spending increases
associated with the new Medicare prescription drug beneﬁt may
be mitigated by reductions in spending on chronic illnesses such
as asthma. As the new drug beneﬁt is designed, attention should
be focused on the identiﬁcation of medications that reduce
overall Medicare spending to insure that they are covered by
drug plans.
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OBJECTIVE: To estimate the annual excess cost of chronic
obstructive pulmonary disease (COPD) to a large managed-care
plan. METHODS: This study employed a retrospective, matched
cohort design and administrative claims data from the large
multi-state managed care database. Patients selected were 35+
years of age, with a diagnosis of COPD in 2001, and eligible for
medical and pharmacy beneﬁts as of January 1, 2001. The com-
parison cohort consisted of patients without COPD matched on
age, gender, geographic region, and insurance coverage type. The
excess cost of COPD was estimated as the difference in mean
health plan payments between the COPD and comparison
cohorts during 2001. Multivariate techniques were employed to
assess the contribution of mortality and comorbidity to excess
costs. RESULTS: A total of 61,527 patients with COPD met
study inclusion criteria, a prevalence of approximately 9%.
Approximately 12% were diagnosed with emphysema, 25%
with chronic bronchitis, and 63% with unclassiﬁed chronic
airway obstruction. COPD patients and their matched controls
(n = 61,527) averaged 71 years of age and 50% were female.
Charlson comorbidities, especially vascular disease and cancer,
were more common in the COPD cohort. The utilization of most
types of services was signiﬁcantly (P < 0.001) higher in the COPD
group, including hospitalizations (43% vs. 14%), emergency
room visits (47% vs. 21%), and home health-care services (28%
vs. 8%). The annual per-patient excess cost of COPD from the
health plan perspective was estimated to be approximately
$7900 ($11,350 for the COPD cohort minus $3450 for the
control cohort), 58% of which was due to hospitalizations. The
higher burden of comorbidity and mortality in the COPD cohort
accounted for about 40% of the observed difference in excess
costs. CONCLUSIONS: The excess cost of COPD is substantial.
Acute hospitalizations and greater comorbidity burden explain
a large portion of these excess costs.
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OBJECTIVE: Recent guidelines have recommended that children
aged 6–24 months should be immunized with inﬂuenza vaccine
to protect against inﬂuenza. Our objective was to evaluate health
outcomes and costs to society of inﬂuenza vaccination on
inﬂuenza and acute otitis media infection in an otherwise healthy
population of 6–24 month old infants. METHODS: Based 
on published and unpublished data, a decision analytical model
comparing two strategies: children vaccinated with inactivated
inﬂuenza vaccine and children not vaccinated children has been
developed. The clinical pathway predicted the probability of
becoming infected with inﬂuenza, developing acute otitis media
in conjunction with inﬂuenza or alone. Health outcomes used in
this model included days of illness as well as days of paid
employment missed by primary caregiver. Costs incorporated
into the model included both direct and indirect costs including
cost of vaccination, pharmaceutical costs of treatment of infec-
tion, hospitalization, and caregiver employment income lost.
Robustness of results was tested by univariate and multivariate
sensitivity analysis. The model was used to simulate the results
for an otherwise health population comparing vaccination to
non-vaccination strategy of care. RESULTS: Vaccination pro-
grams had lower cost and better health outcomes when com-
pared to non-vaccination programs. Vaccinated children had an
expected cost to society of $329.51 with 2.29 expected days of
illness and 1.93 days of work missed by the primary caregiver.
Non-vaccinated children had an expected cost of $393.78 with
3.97 expected days of illness and 2.63 days of work missed by
the primary caregiver. Univariate and multivariate sensitivity
analysis showed these results to be robust in upholding vaccina-
tion as a cost effective alternative to no vaccination over a wide
range of assumptions. CONCLUSION: Immunization with inac-
tivated inﬂuenza vaccine is a cost effective treatment in reducing
the incidence of both inﬂuenza and acute otitis media for chil-
dren aged 6–24 months.
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OBJECTIVE: This study evaluates the projected cost-
effectiveness of antiviral treatments (amantadine or oseltamivir)
with and without the use of inﬂuenza rapid tests in children.
METHODS: A decision tree was developed to predict costs and
health effects of 5 strategies: no antiviral treatment, empirical
treatment with amantadine, empirical treatment with
oseltamivir, testing then treatment with amantadine, and testing
then treatment with oseltamivir. The target population was strat-
iﬁed by age (6–23mos, 2yrs, 3–4yrs, 5–11yrs, and 12–17yrs)
and risk status (high or low risk for inﬂuenza-related complica-
tions). Probabilities and costs (direct and opportunity) for
uncomplicated inﬂuenza, inﬂuenza-like illness, outpatient visits,
hospitalizations, deaths, effectiveness of antiviral treatments,
treatment adverse events, and characteristics of inﬂuenza rapid
tests were based on primary and secondary data. Quality adjust-
